ACR logo

Acrux Stock Price

Symbol: ASX:ACRMarket Cap: AU$6.9mCategory: Pharmaceuticals & Biotech

ACR Share Price Performance

ACR Community Fair Values

Recent ACR News & Updates

No updates

Acrux Limited Key Details

AU$802.0k

Revenue

AU$2.6m

Cost of Revenue

-AU$1.8m

Gross Profit

AU$4.2m

Other Expenses

-AU$6.0m

Earnings

Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
Earnings per share (EPS)
-0.015
Gross Margin
-226.68%
Net Profit Margin
-746.38%
Debt/Equity Ratio
0%

Acrux Limited Competitors

 
 
 
 
 
 
 
 
 
 
 
 

About ACR

Founded
1998
Employees
n/a
CEO
John Warmbrunn
WebsiteView website
www.acrux.com.au

Acrux Limited, together with its subsidiaries, engages in the development and commercialization of generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause; Dapsone 5% and Dapsone 7.5% which are gels for the treatment of acne vulgaris; and Prilocaine 2.5% and Lidocaine 2.5%, a topical anaesthetic cream. It is also involved in the development of Efinaconazole, a topical solution used to treat fungal infections of toenails; Nitroglycerin 0.4%, an ointment for the treatment of pain caused by chronic anal fissure; and Acyclovir 5%, a cream for the treatment of cold sores. The company was incorporated in 1998 and is based in West Melbourne, Australia.

Australian Market Performance

  • 7 Days: -0.2%
  • 3 Months: 5.5%
  • 1 Year: 8.6%
  • Year to Date: 5.1%
Over the last 7 days, the market has remained flat, although notably the Materials sector declined by 4.2%. Meanwhile, the market is actually up 8.6% over the past year. As for the next few years, earnings are expected to grow by 11% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading